hydroxychloroquine has been researched along with Cardiovascular Pregnancy Complications in 8 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The worldwide incidence of coronavirus disease 2019 (COVID-19) infection is rapidly increasing, but there exists limited information on coronavirus disease 2019 in pregnancy." | 1.56 | Coronavirus disease 2019 in pregnancy: early lessons. ( Baptiste, C; Breslin, N; D'Alton, M; Fuchs, K; Goffman, D; Gyamfi-Bannerman, C; Miller, R, 2020) |
| "Thus, the pregnancy was considered a high-risk pregnancy." | 1.42 | [Systemic lupus erythematosus and a medical history of deep vein thrombosis in a 27-year-old pregnant woman]. ( Puppe, V, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Juusela, A | 1 |
| Nazir, M | 1 |
| Gimovsky, M | 1 |
| Breslin, N | 1 |
| Baptiste, C | 1 |
| Miller, R | 1 |
| Fuchs, K | 1 |
| Goffman, D | 1 |
| Gyamfi-Bannerman, C | 1 |
| D'Alton, M | 1 |
| Ortiz Molina, E | 1 |
| Hernandez Pailos, R | 1 |
| Pola Guillen, M | 1 |
| Pascual Pedreno, A | 1 |
| Rodriguez Rodriguez, E | 1 |
| Hernandez Martinez, A | 1 |
| Gan, SP | 1 |
| Ong, SG | 1 |
| Puppe, V | 1 |
| Merashli, M | 1 |
| Noureldine, MH | 1 |
| Uthman, I | 1 |
| Khamashta, M | 1 |
| Chaturvedi, S | 1 |
| McCrae, KR | 1 |
| Izmirly, PM | 1 |
| Costedoat-Chalumeau, N | 1 |
| Pisoni, CN | 1 |
| Khamashta, MA | 1 |
| Kim, MY | 1 |
| Saxena, A | 1 |
| Friedman, D | 1 |
| Llanos, C | 1 |
| Piette, JC | 1 |
| Buyon, JP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Trial Evaluating Effect of Outpatient Hydroxychloroquine on Reducing Hospital Admissions in Pregnant Women With SARS-CoV-2 Infection: HyPreC Trial[NCT04354441] | Phase 2 | 0 participants (Actual) | Interventional | 2020-05-31 | Withdrawn (stopped due to Not started) | ||
| Home Monitoring of Fetal Heart Rhythm in Pregnancies of Anti-Ro/SSA Positive Women for the Treatment of Congenital Heart Block (FETAL HOPE)[NCT05958446] | 200 participants (Anticipated) | Observational | 2022-04-14 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for hydroxychloroquine and Cardiovascular Pregnancy Complications
| Article | Year |
|---|---|
Antiphospholipid syndrome: an update.
Topics: Adrenal Cortex Hormones; Animals; Annexin A2; Anticoagulants; Antiphospholipid Syndrome; Drugs, Inve | 2015 |
The antiphospholipid syndrome: still an enigma.
Topics: Administration, Oral; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; beta | 2015 |
6 other studies available for hydroxychloroquine and Cardiovascular Pregnancy Complications
| Article | Year |
|---|---|
Two cases of coronavirus 2019-related cardiomyopathy in pregnancy.
Topics: Adult; Anti-Arrhythmia Agents; Antibodies, Monoclonal, Humanized; Anticonvulsants; Blood Gas Analysi | 2020 |
Coronavirus disease 2019 in pregnancy: early lessons.
Topics: Acute Kidney Injury; Adult; Anesthesia, General; Anti-Bacterial Agents; Antihypertensive Agents; Azi | 2020 |
COVID-19 infection in symptomatic pregnant women at the midpoint of the pandemic in Spain: a retrospective analysis.
Topics: Adult; Anosmia; Anti-Bacterial Agents; Anticoagulants; Antiviral Agents; C-Reactive Protein; Cesarea | 2020 |
Antithrombotic effects of hydroxychloroquine in a pregnant patient with Antiphospholipid syndrome and recurrent venous thromboembolism.
Topics: Antiphospholipid Syndrome; Antithrombins; Female; Humans; Hydroxychloroquine; Pregnancy; Pregnancy C | 2017 |
[Systemic lupus erythematosus and a medical history of deep vein thrombosis in a 27-year-old pregnant woman].
Topics: Adult; Antirheumatic Agents; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Hyd | 2015 |
Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus.
Topics: Adult; Antibodies, Antinuclear; Cohort Studies; Databases, Factual; Female; France; Humans; Hydroxyc | 2012 |
Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus.
Topics: Adult; Antibodies, Antinuclear; Cohort Studies; Databases, Factual; Female; France; Humans; Hydroxyc | 2012 |
Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus.
Topics: Adult; Antibodies, Antinuclear; Cohort Studies; Databases, Factual; Female; France; Humans; Hydroxyc | 2012 |
Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus.
Topics: Adult; Antibodies, Antinuclear; Cohort Studies; Databases, Factual; Female; France; Humans; Hydroxyc | 2012 |